title: Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study.
authors.affiliation: Rotterdam Cancer Institute, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Stoter
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: C
authors.initials: C
authors.lastname: Rugarli
authors.forename: M
authors.initials: M
authors.lastname: Symann
authors.forename: C
authors.initials: C
authors.lastname: Jasmin
authors.forename: L
authors.initials: L
authors.lastname: Israel
authors.forename: J T
authors.initials: JT
authors.lastname: Bijman
authors.forename: P
authors.initials: P
authors.lastname: Palmer
authors.forename: C R
authors.initials: CR
authors.lastname: Franks
authors.forename: T
authors.initials: T
authors.lastname: Philip
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011379:Prognosis
chemical_list: D007376:Interleukin-2